aromasil has been researched along with Bone Loss, Osteoclastic in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (83.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baselga, J; Burris, HA; Campone, M; Eakle, J; El-Hashimy, M; Geberth, M; Gnant, M; Hadji, P; Hart, LL; Hortobagyi, GN; Iwata, H; Lebwohl, D; Mukai, H; Noguchi, S; Piccart, M; Pritchard, KI; Rao, S; Rugo, HS; Sahmoud, T; Taran, T | 1 |
| Hadji, P; Hasenburg, A; Kalder, M; Kieback, DG; Kuck, J; Menschik, T; Ziller, M | 1 |
| Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H | 1 |
| Goss, PE; Grynpas, MD; Hu, H; Josse, RG; Mendes, M; Pritzker, KP; Qi, S; Waldman, SD | 1 |
| Tanvetyanon, T | 1 |
| Mouridsen, HT | 1 |
| Bliss, JM; Coombes, RC; Hall, E | 1 |
| Bremnes, Y; Erikstein, B; Geisler, J; Hagen, AI; Krag, LE; Lien, EA; Lønning, PE; Massimini, G; Ofjord, ES; Paolini, J; Polli, A; Schlichting, E | 1 |
| Shapiro, CL | 1 |
| Cadirni, A; Caffarelli, C; Franci, MB; Francini, G; Gonnelli, S; Lucani, B; Montagnani, A; Nuti, R; Petrioli, R | 1 |
| Abreu, P; Banke-Bochita, J; Goss, PE; Hadji, P; Subar, M; Thomsen, T | 1 |
| Clack, G; Eastell, R; Finkelman, RD; Fraser, WD; Hannon, RA; Lakner, G; McCloskey, EV; Miyamoto, A | 1 |
7 trial(s) available for aromasil and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Topics: Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Middle Aged; Odds Ratio; Osteogenesis; Postmenopause; Procollagen; Proportional Hazards Models; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Topics: Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Collagen Type I; Female; Follow-Up Studies; Humans; Middle Aged; Osteocalcin; Peptides; Tamoxifen; Time Factors; Treatment Outcome | 2009 |
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Resorption; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2010 |
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Resorption; Breast Neoplasms; Double-Blind Method; Female; Humans; Lipids; Middle Aged; Placebos; Postmenopause | 2005 |
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
Topics: Alkaline Phosphatase; Androstadienes; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Female; Humans; Middle Aged; Peptides; Radiography; Tamoxifen | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Lipids; Menopause; Middle Aged; Nitriles; Peptide Fragments; Placebos; Procollagen; Single-Blind Method; Tamoxifen; Triazoles | 2007 |
Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.
Topics: Adrenal Glands; Alkaline Phosphatase; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers; Body Mass Index; Bone and Bones; Bone Remodeling; Bone Resorption; Female; Humans; Letrozole; Lipids; Middle Aged; Nitriles; Postmenopause; Triazoles | 2007 |
5 other study(ies) available for aromasil and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.
Topics: Androstadienes; Animals; Aromatase; Aromatase Inhibitors; Bone Resorption; Enzyme Inhibitors; Female; Femur; Lumbar Vertebrae; Ovariectomy; Rats; Rats, Sprague-Dawley | 2004 |
Adjuvant treatment of breast cancer with exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Osteoporosis; Tamoxifen | 2004 |
Exemestane following tamoxifen in postmenopausal women with primary breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Risk Factors; Tamoxifen | 2004 |
Safety of exemestane in the Intergroup Exemestane Study.
Topics: Androstadienes; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Research Design; Time Factors | 2005 |
Aromatase inhibitors and bone loss: risks in perspective.
Topics: Androstadienes; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Humans; Randomized Controlled Trials as Topic; Risk Factors | 2005 |